MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1089/jpm.2018.0272

Медицинская библиотека · Journal of palliative medicine · 2018

Morphine for Refractory Dyspnea in Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05).

Matsuda Yoshinobu, Morita Tatsuya, Miyaji Tempei, Ogawa Tomoko, Kato Kuniko, Kawaguchi Takashi, Tokoro Akihiro, Iwase Satoru, Yamaguchi Takuhiro, Inoue Yoshikazu

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Background

Dyspnea is common in interstitial lung disease (ILD) patients and often refractory to conventional treatment. Little is known regarding the safety of systemic morphine in ILD patients.

Objective

The objective of this study is to evaluate the safety of a single subcutaneous morphine injection and to determine the recommended dose of morphine for alleviating dyspnea in ILD patients.

Design

We conducted a dose-escalation Phase I study for investigating the recommended dose of a single subcutaneous morphine injection to alleviate dyspnea in ILD patients. Setting/Subjects: Eligible subjects were ILD inpatients with dyspnea at rest who were refractory to conventional dyspnea treatment. The morphine doses used were 1 mg and 2 mg in cohort 1 and cohort 2, respectively. The primary endpoint was dose-limiting toxicity, which was defined as (1) respiratory depression, that is, 30% reduction of respiratory rate and 10 Torr increase of PaCO2 compared with baseline; (2) hypotension, that is, 20% reduction of systemic blood pressure compared with baseline and presentation of hypotension-related symptoms; or (3) grade 3, 4, or 5 treatment-emergent adverse events graded by Common Terminology Criteria for Adverse Events (version 4).

Results

A total of six patients were enrolled, with three patients each in cohorts 1 and 2. No dose-limiting toxicities were observed; three patients experienced worsened somnolence, but no patients experienced sedation.

Conclusion

We conclude that 2 mg of morphine has a tolerable safety profile in ILD patients with dyspnea, and can be tested in further clinical trials.

Для цитирования: Matsuda Yoshinobu, Morita Tatsuya, Miyaji Tempei, Ogawa Tomoko, Kato Kuniko, Kawaguchi Takashi, Tokoro Akihiro, Iwase Satoru, Yamaguchi Takuhiro, Inoue Yoshikazu. Morphine for Refractory Dyspnea in Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05).. Journal of palliative medicine. 2018. DOI: 10.1089/jpm.2018.0272.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.